Geron Announces FDA Acceptance Of New Drug Application For Imetelstat For The Treatment Of Lower Risk MDS
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Geron Corporation's new drug application for Imetelstat, a treatment for lower risk Myelodysplastic Syndromes (MDS).
August 21, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron Corporation's new drug application for Imetelstat has been accepted by the FDA. This could potentially lead to increased revenues for the company if the drug is approved and successfully marketed.
The FDA's acceptance of Geron's new drug application is a significant step towards the drug's approval. If approved, Imetelstat could generate substantial revenues for Geron, especially considering the lack of effective treatments for lower risk MDS. This could potentially lead to a positive impact on Geron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100